skip to the content

Clinical Trials

Acute Myeloid Leukemia Study

CALGB 10502: Dose Escalation and Phase II Study of Bortezomib Added to Standard Danunoriubicin and Cytarabine Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 years

Protocol ID

08-255

Protocol Description

The purpose of this study is to test the safety and effectiveness of the addition of the experimental drug bortezomib to a treatment regimen for patients with acute myeloid leukemia (AML), and to see the effects (good and bad) of bortezomib.

Eligibility Criteria

Patients with acute myeloid leukemia (AML)

Primary Investigator(s)

  • Jonathan Kolitz, MD

Contact Information

Jennifer Cuevo, RN
(516) 562-8920
jcuevo@nshs.edu

Last Update

March 25, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Cancer:
top
top